Iradimed reports record Q3 revenue of $21.2M, up 16% YoY; raises FY2025 guidance

IRADIMED CORP

2025-Q3 EPS reported $1.25 revenue$61,122,101

GAAP diluted EPS $0.43, non-GAAP diluted EPS $0.47; net income $5.6M (+10% YoY).
Full-year 2025 guidance raised: revenue $82.5M-$83.5M, GAAP EPS $1.68-$1.72, non-GAAP EPS $1.84-$1.88.
Declares quarterly dividend of $0.17/share, payable Nov 25, 2025, record date Nov 14, 2025.
Next-generation 3870 MRI-compatible IV pump on track for limited commercial shipments Dec 2025, full rollout Q1 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.